Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says
Executive Summary
Treatment with Roche's Pegasys/Copegus should be dosed according to hepatitis C virus genotype in order to optimize the product's risk/benefit ratio, FDA's Antiviral Drugs Advisory Committee recommended
You may also be interested in...
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments
Roche Pegasys/Copegus Monitoring For Severe Infections Advised By Cmte.
Hepatitis C patients receiving Roche's Pegasys/ Copegus should be actively monitored for hematologic abnormalities and infections, FDA's Antiviral Drugs Advisory Committee recommended Nov. 14